Why is it infused into the brain?

TPP1 cannot cross the blood-brain barrier from the bloodstream, so the enzyme is delivered directly into the brain's ventricles through an implanted reservoir.

Does it cure CLN2 disease?

No. Trials show it slows the decline in motor and language function compared with untreated children, but it does not cure the disease.

What are the main risks?

The biggest risks come from the implanted delivery device (infections such as meningitis, device failure or leak) plus infusion reactions, seizures and heart-rate changes, requiring monitoring during each infusion.

EMA-approvedaka Brineura

Cerliponase alfa — Complete Research Guide (2026)

Q: Is it approved?

Yes. It is approved by both the US FDA and the European Medicines Agency (2017) to slow loss of ambulation in symptomatic children with CLN2 disease.

Last updated 2026-06-30

TL;DR

Cerliponase alfa (also known as Brineura) is a peptide catalogued under Enzymes (CLN2 disease). Neutral reference entry; EU status: EU-approved prescription medicine.

What is Cerliponase alfa?

Cerliponase alfa (brand name Brineura) is a recombinant human tripeptidyl peptidase-1 (TPP1) used as enzyme replacement therapy for CLN2 disease (neuronal ceroid lipofuscinosis type 2, also called late-infantile Batten disease), a fatal childhood neurodegenerative disorder caused by TPP1 deficiency.

It is approved by both the US FDA and the European Medicines Agency (2017) to slow loss of ambulation, and is uniquely administered directly into the brain's ventricles rather than intravenously.

Approval was supported by a human open-label trial compared against a natural-history cohort, with efficacy on slowing motor-language decline.

How does Cerliponase alfa work?

Cerliponase alfa is a proenzyme that is delivered into the cerebrospinal fluid, taken up by cells and converted in the lysosome to active TPP1, which cleaves tripeptides from proteins and clears the storage material that otherwise destroys neurons.

Because TPP1 does not cross the blood-brain barrier from the bloodstream, the drug is infused intracerebroventricularly to reach the central nervous system where CLN2 causes its damage.

What does the research say about Cerliponase alfa?

In the pivotal open-label trial, intracerebroventricular cerliponase alfa slowed the decline in combined motor and language function compared with an untreated natural-history cohort. ^[1]
A long-term open-label extension showed the slowing of motor-language decline was sustained over several years of continued treatment. ^[2]
Natural-history data show untreated CLN2 causes rapid, predictable motor and language deterioration, providing the comparator against which the treatment benefit is measured. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Study of Intraventricular Cerliponase Alfa for CLN2 Disease — Schulz A et al., New England Journal of Medicine 2018. (Open-label trial vs natural-history controls)
[2] Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study — Schulz A et al., Lancet Neurology 2024. (Open-label long-term extension)
[3] Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study — Nickel M et al., Lancet Child and Adolescent Health 2018. (Observational natural-history cohort)
[4] Cerliponase Alfa: First Global Approval — Markham A et al., Drugs 2017. (Regulatory review article)
[5] Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 — Lewis G et al., Journal of Child Neurology 2020. (Narrative review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In the trials the regimen was 300 mg infused into the cerebral ventricles once every other week via the implanted reservoir, given slowly over several hours with premedication.

This is background on how the drug was studied, not clinical guidance; it must be administered only by clinicians experienced in intracerebroventricular delivery.

Side effects & safety profile

Because the drug is given through a surgically implanted intracerebroventricular reservoir and catheter, the most serious risks relate to the delivery device, including device-related infections (meningitis), device failure or leakage, and the need for surgical revision.

Infusion-related adverse effects reported in trials include fever, vomiting, seizures, hypersensitivity reactions, and transient changes in heart rate (bradycardia) and blood pressure, so cardiac and neurological monitoring is required during infusions.

Cerebrospinal fluid should be monitored for infection, and the device should not be used if there are signs of leakage or CNS infection.

Stacking & combinations

It is a hospital-administered rare-disease biologic delivered directly into the brain and is used as disease-specific monotherapy alongside supportive and symptomatic care, not in any combination stack.

Finding Cerliponase alfa vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It treats CLN2 disease (late-infantile Batten disease) by replacing the missing brain enzyme TPP1 to slow loss of walking and language ability.

References

[1] Study of Intraventricular Cerliponase Alfa for CLN2 Disease — Schulz A et al., New England Journal of Medicine 2018. PMID: 29688815. View sourceStudy: Open-label trial vs natural-history controlsIntracerebroventricular cerliponase alfa slowed the decline in motor and language function versus untreated historical controls.
[2] Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study — Schulz A et al., Lancet Neurology 2024. PMID: 38101904. View sourceStudy: Open-label long-term extensionThe slowing of motor-language decline was sustained over long-term continued treatment.
[3] Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study — Nickel M et al., Lancet Child and Adolescent Health 2018. PMID: 30119717. View sourceStudy: Observational natural-history cohortUntreated CLN2 disease follows a rapid and predictable course of motor and language deterioration.
[4] Cerliponase Alfa: First Global Approval — Markham A et al., Drugs 2017. PMID: 28589525. View sourceStudy: Regulatory review articleSummarizes the development and first global regulatory approval of cerliponase alfa for CLN2 disease.
[5] Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 — Lewis G et al., Journal of Child Neurology 2020. PMID: 31884868. View sourceStudy: Narrative reviewReviews efficacy, intracerebroventricular delivery and device-related safety considerations of cerliponase alfa.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.